Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported revenue above consensus and reiterated 2019 guidance. Revenue totaled $400.7 million, or 13% percent better quarter over quarter and 7% better year over year. Vimizim (elosulfase alfa) sales reached $125.8 million, or 10% better quarter over quarter and 7% better year over year. Aldurazyme (laronidase) revenues totaled $45.3 million and Naglazyme (galsulfase) sales were $86.9 million.